Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosmanogepix - Amplyx Pharmaceuticals

Drug Profile

Fosmanogepix - Amplyx Pharmaceuticals

Alternative Names: APX-001

Latest Information Update: 29 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Co Ltd
  • Developer Amplyx Pharmaceuticals
  • Class Aminopyridines; Antifungals; Antineoplastics; Oxazoles; Phosphates; Small molecules
  • Mechanism of Action Enzyme inhibitors; GWT1 protein inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Coccidioidomycosis; Candidiasis; Mycoses; Cryptococcosis; Aspergillosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Aspergillosis; Candidaemia
  • Phase I Acute myeloid leukaemia; Mycoses
  • Preclinical Coccidioidomycosis

Most Recent Events

  • 28 Apr 2021 Amplyx Pharmaceuticals has been acquired by Pfizer
  • 18 Mar 2021 Amplyx Pharmaceuticals completes a phase I trial in Mycoses (In volunteers) in United Kingdom (PO; IV) (NCT04804059)
  • 31 Dec 2020 Amplyx Pharmaceuticals completes the phase II APEX trial for Candidaemia in South Africa and Panama (NCT04148287)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top